MYCOSIS FUNGOIDES

This study tests whether a treatment called photopheresis, which filters and treats a patient's blood with light, can help people with early-stage cutaneous T-cell lymphoma (a type of skin cancer). Currently used only for advanced disease, researchers want to see if using it earl…

This early-phase study tests a combination of two drugs, mogamulizumab and brentuximab vedotin, in people with a rare type of skin lymphoma (CTCL or MF) that has been treated before. The main goal is to find a safe dose and understand side effects. About 10 adults with advanced d…

This study tracks 15 adults with mycosis fungoides or Sezary syndrome who receive mogamulizumab, a targeted antibody therapy, in everyday medical practice. Researchers will record side effects and measure how well the drug controls the cancer using a standard scoring system. The …

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory p…

This early-stage trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the i…

This early-phase trial tests a new drug called ST-001 in people with T-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to find the safest dose and to watch for side effects. About 46 participants will receive the drug through a…

This study tests a lower dose of the drug brentuximab vedotin in people with mycosis fungoides, Sezary syndrome, or lymphomatoid papulosis—types of lymphoma that affect the skin. The goal is to see if the lower dose can still control the disease while causing fewer side effects. …

This study tests whether adding a topical immune-stimulating cream (imiquimod) to standard local radiation therapy can improve treatment of mycosis fungoides, a rare skin lymphoma. About 25 adults with early-stage disease who have not responded to at least one prior therapy will …

This study tests a very low dose of radiation to the whole skin combined with a targeted drug called brentuximab vedotin. The goal is to see if this combination can better control mycosis fungoides, a rare type of skin lymphoma. About 30 adults with the disease that has come back…

This study tests a gel called HyBryte, which is activated by visible light, to treat a rare type of skin lymphoma (CTCL). About 80 adults with early-stage disease will apply the gel to their skin lesions and then receive light treatment. The goal is to see if the gel can shrink o…

This study tests whether very low doses of radiation can control skin lesions in people with mycosis fungoides, a type of lymphoma. About 50 participants will receive targeted radiation to their skin spots. The goal is to see if this gentler approach works as well as standard rad…

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have come back or not responded to prior therapy. About 48 adults will receive the drug to see if it can shrink tumors and control the disease. The goal is to improv…

This study follows 100 people who were diagnosed with juvenile-onset mycosis fungoides or lymphomatoid papulosis before age 20. Researchers will check their health status and ask about long-term outcomes. The goal is to understand the safety and long-term effects of these rare sk…

This study is collecting medical information from 2,000 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The goal is to create a new tool that helps doctors predict which patients are at higher or lower risk, so they can choose the best trea…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research to better understand these skin conditions. Participants must be 18 or older and have a…